| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Kai W Wucherpfennig | |
| Katherine A McLaughlin | |||
| P2860 | cites work | Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica | Q21144670 |
| Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness | Q22252384 | ||
| The prevalence of multiple sclerosis in the world: an update | Q22252675 | ||
| Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 | ||
| IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel | Q24646531 | ||
| Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells | Q42753323 | ||
| Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. | Q42802801 | ||
| Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. | Q44223059 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses | Q45302161 | ||
| Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions | Q46116317 | ||
| Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination | Q46208130 | ||
| Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 | ||
| Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis | Q78952359 | ||
| Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders | Q80235246 | ||
| Passive induction of experimental allergic encephalomyelitis | Q80285957 | ||
| Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire | Q80350835 | ||
| Antigen presentation and transfer between B cells and macrophages | Q80397299 | ||
| Investigation of the role of B-cells in type 1 diabetes in the NOD mouse | Q80787816 | ||
| B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism | Q81317325 | ||
| Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis | Q81335025 | ||
| Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis | Q81401055 | ||
| Immunology of multiple sclerosis | Q81531267 | ||
| Multiple sclerosis | Q81574168 | ||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors | Q81772313 | ||
| High-dose rituximab and anti-MAG-associated polyneuropathy | Q82809993 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein | Q24681234 | ||
| Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event | Q28186287 | ||
| Regulation of T:B cell interactions by the inducible costimulator molecule: does ICOS "induce" disease? | Q28247470 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 | Q28283861 | ||
| Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats | Q28578012 | ||
| Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation | Q28585845 | ||
| Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Axonal transection in the lesions of multiple sclerosis | Q29615585 | ||
| A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis | Q29615952 | ||
| Multiple sclerosis | Q29616022 | ||
| Germinal centers | Q29616234 | ||
| Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response | Q30854079 | ||
| Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination | Q31076579 | ||
| Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. | Q31110030 | ||
| Clinically isolated syndromes: predicting and delaying multiple sclerosis | Q31115404 | ||
| The spectrum of neuromyelitis optica | Q31122077 | ||
| Restricted use of VH4 germline segments in an acute multiple sclerosis brain | Q32107477 | ||
| Helper T cells in antibody-mediated, organ-specific autoimmunity | Q33335330 | ||
| A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. | Q33882987 | ||
| Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children | Q33926778 | ||
| Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. | Q33941343 | ||
| Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients | Q33962031 | ||
| Postinfectious encephalomyelitis | Q33965417 | ||
| Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features | Q33980439 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| New diagnostic criteria for multiple sclerosis: guidelines for research protocols | Q34271601 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Basic principles of immunological surveillance of the normal central nervous system | Q34398602 | ||
| Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis | Q34458130 | ||
| Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. | Q34479121 | ||
| B-cell targeting in rheumatoid arthritis and other autoimmune diseases | Q34514813 | ||
| Lymphoid neogenesis in chronic inflammatory diseases. | Q36405080 | ||
| Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? | Q36432489 | ||
| Th17: the third member of the effector T cell trilogy | Q36528977 | ||
| Checkpoints in memory B-cell evolution | Q36529012 | ||
| Pathogenesis and treatment of systemic lupus erythematosus nephritis | Q36560135 | ||
| The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration | Q36610350 | ||
| Antigen presentation by B lymphocytes: how receptor signaling directs membrane trafficking | Q36671102 | ||
| Challenges in the classification of pediatric multiple sclerosis and future directions | Q36793461 | ||
| Germinal centres: role in B-cell physiology and malignancy | Q37039584 | ||
| Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS | Q37258223 | ||
| Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes | Q37371756 | ||
| Analysis of Chlamydia pneumoniae-specific oligoclonal bands in multiple sclerosis and other neurologic diseases | Q37863995 | ||
| Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica | Q38429895 | ||
| Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes | Q39676482 | ||
| Visualization of antigen presentation by actin-mediated targeting of glycolipid-enriched membrane domains to the immune synapse of B cell APCs | Q40592184 | ||
| Signal transduction by the B cell antigen receptor and its coreceptors | Q40661147 | ||
| The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen | Q40837236 | ||
| Production of cytokines by human B cells in health and disease | Q41546341 | ||
| B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions | Q41697260 | ||
| Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis | Q41788436 | ||
| BCR ubiquitination controls BCR-mediated antigen processing and presentation | Q41841391 | ||
| B-cell-targeted therapy for systemic lupus erythematosus | Q42603286 | ||
| Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients | Q42619341 | ||
| An open label study of the effects of rituximab in neuromyelitis optica | Q46482210 | ||
| Lipid microarrays identify key mediators of autoimmune brain inflammation | Q46845275 | ||
| B-lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluid | Q47242758 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects | Q47376541 | ||
| Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association | Q47897582 | ||
| Distinct profiles of human B cell effector cytokines: a role in immune regulation? | Q47992004 | ||
| Active induction of experimental allergic encephalomyelitis | Q48175463 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis | Q48282187 | ||
| Antimyelin antibodies with no progression to multiple sclerosis. | Q48298505 | ||
| Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue | Q48317593 | ||
| B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization | Q48364459 | ||
| Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination | Q48489118 | ||
| A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody | Q48630477 | ||
| Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. | Q48823528 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. | Q51763866 | ||
| Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. | Q51908610 | ||
| First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. | Q51943633 | ||
| B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. | Q52032016 | ||
| A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. | Q52039800 | ||
| Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. | Q52544618 | ||
| Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). | Q52832777 | ||
| Systemic lupus erythematosus. | Q53495545 | ||
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. | Q53555780 | ||
| Acute disseminated encephalomyelitis | Q56038008 | ||
| Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis | Q57753793 | ||
| Primary progressive multiple sclerosis | Q57912056 | ||
| A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | Q58204906 | ||
| Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells | Q58323390 | ||
| Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope | Q59060541 | ||
| Antigen-specific interaction between T and B cells | Q59063745 | ||
| Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations | Q59273833 | ||
| Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis | Q59273850 | ||
| Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study | Q59273880 | ||
| Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange | Q61709608 | ||
| A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination | Q61709649 | ||
| Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown | Q70180407 | ||
| Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies | Q71150178 | ||
| A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group | Q71230101 | ||
| Autoantibodies to myelin basic protein are not present in the serum and CSF of MS patients | Q71659009 | ||
| The adhesion molecule and cytokine profile of multiple sclerosis lesions | Q71688111 | ||
| B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide | Q73170385 | ||
| Reciprocal regulation of polarized cytokine production by effector B and T cells | Q73256871 | ||
| Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies | Q73301091 | ||
| Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function | Q73419615 | ||
| Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients | Q73438121 | ||
| Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein | Q74456215 | ||
| Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study | Q74607777 | ||
| TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group | Q78130683 | ||
| Revised diagnostic criteria for neuromyelitis optica | Q34529345 | ||
| Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression | Q34546279 | ||
| Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. | Q34569888 | ||
| Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study | Q34581641 | ||
| Oligoclonal bands and antibody responses in multiple sclerosis | Q34609976 | ||
| Consensus definitions proposed for pediatric multiple sclerosis and related disorders | Q34619721 | ||
| Transvascular delivery of small interfering RNA to the central nervous system. | Q34638044 | ||
| Unravelling the pathogenesis of myasthenia gravis | Q34931975 | ||
| Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. | Q35009513 | ||
| Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice | Q35009518 | ||
| Lymphotoxin/light, lymphoid microenvironments and autoimmune disease | Q35219029 | ||
| Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. | Q35539775 | ||
| Plasma-cell homing | Q35549150 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance | Q35605693 | ||
| Rituximab: expanding role in therapy for lymphomas and autoimmune diseases | Q35640302 | ||
| Rheumatoid factor revisited | Q35753685 | ||
| Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. | Q35769109 | ||
| Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein | Q35818687 | ||
| Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions | Q35819856 | ||
| The importance of early diagnosis of multiple sclerosis. | Q35836357 | ||
| Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein | Q35891689 | ||
| Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. | Q36074614 | ||
| Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. | Q36082102 | ||
| Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein | Q36194449 | ||
| Neurofascin as a novel target for autoantibody-mediated axonal injury | Q36228999 | ||
| SLE: translating lessons from model systems to human disease | Q36254076 | ||
| B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice | Q36367653 | ||
| Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis | Q36368128 | ||
| A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus | Q36369955 | ||
| Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. | Q36370963 | ||
| B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. | Q36400576 | ||
| The sequential role of lymphotoxin and B cells in the development of splenic follicles. | Q36400592 | ||
| Abortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo. | Q36400871 | ||
| P921 | main subject | autoantibody | Q785022 |
| multiple sclerosis | Q8277 | ||
| P304 | page(s) | 121-149 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Advances in Immunology | Q15752932 |
| P1476 | title | B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases | |
| P478 | volume | 98 |
| Q37818921 | A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis |
| Q37419038 | Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations |
| Q37766015 | Animal models of multiple sclerosis--potentials and limitations |
| Q33620003 | Autoimmune T cell responses in the central nervous system |
| Q35298764 | B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes |
| Q41820142 | CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis |
| Q46159575 | Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis |
| Q33837769 | Coherent somatic mutation in autoimmune disease |
| Q38851770 | DNA Methylation: a New Player in Multiple Sclerosis |
| Q37867728 | Development of anti-CD20 therapy for multiple sclerosis. |
| Q57562078 | Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions |
| Q98177704 | From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment |
| Q34479298 | Glatiramer acetate for treatment of MS: Regulatory B cells join the cast of players |
| Q39802246 | Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future |
| Q43104143 | Immunity and inflammation in neurodegenerative diseases |
| Q63363253 | Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE |
| Q36330016 | Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins |
| Q37814815 | Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges |
| Q89830634 | Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides |
| Q83462653 | Ophthalmopathology in rats with MBP-induced experimental autoimmune encephalomyelitis |
| Q33777821 | Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF. |
| Q37445439 | Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. |
| Q34409447 | Practical considerations on the use of rituximab in autoimmune neurological disorders |
| Q37463568 | Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis |
| Q37803419 | Roles for lysophospholipid S1P receptors in multiple sclerosis |
| Q37774281 | The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. |
| Q35155753 | The double-edged sword of autoimmunity: lessons from multiple sclerosis |
| Q38186206 | The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. |
| Q36016271 | The skin, a novel niche for recirculating B cells. |
| Q38192844 | To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis |
| Q37505364 | Tolerogenic vaccines for Multiple sclerosis |
Search more.